Drug Trial Radar · NCT07258979
A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.
Last checked: Nov 19, 2026Latest source record: Dec 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
202
Planned (sponsor's estimate)
Start
Nov 5, 2025
Primary completion
Feb 2028
Study completion May 2028
Sponsor
- Lead sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 2, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, open-label, Phase Ib/II study conducted in China to evaluate the safety, efficacy, and pharmacokinetic (PK) characteristics of YL201 combined with Toripalimab (doublet regimen) or YL201 combined with Toripalimab and Cisplatin (triplet regimen) in subjects with recurrent or metastatic nasopharyngeal carcinoma.
Conditions
- Recurrent or Metastatic Nasopharyngeal Carcinoma
Interventions
YL201Drug
YL201 will be administered as an IV infusion
ToripalimabDrug
Toripalimab will be administered as an IV infusion
CisplatinDrug
Cisplatin will be administered as an IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Experiencing Dose-limiting toxicities (DLTs)Time frame: Approximately within 36 months
- Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)Time frame: Approximately within 36 months
- Progression-Free Survival (PFS) as assessed by RECIST v1.1Time frame: Approximately within 36 months
Locations
20 sites in 1 country. Site status is shown where the registry gives one.
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, China · Not yet recruiting
Fujian Cancer Hospital
Fuzhou, Fujian, China · Not yet recruiting
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, China · Not yet recruiting
Zhangzhou Municiple Hospital of Fujian Province
Zhangzhou, Fujian, China · Not yet recruiting
Dongguan People's Hospital
Dongguan, Guangdong, China · Not yet recruiting
Affiliated Cancer Hospital and Institute of Guangzhou Medical University
Guangzhou, Guangdong, China · Not yet recruiting
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China · Recruiting
The First Affiliated Hospital of Guangdong Pharmaceutical University
Guangzhou, Guangdong, China · Not yet recruiting
Jiangmen Central Hospital
Jiangmen, Guangdong, China · Not yet recruiting
Yuebei People's Hospital
Shaoguan, Guangdong, China · Not yet recruiting
The Second Affiliated Hospital of Guilin Medical University
Guilin, Guangxi, China · Not yet recruiting
Guangxi Medical University Cancer Hospital
Nanning, Guangxi, China · Not yet recruiting
The First Affiliated Hospital of Hainan Medical University
Haikou, Hainan, China · Not yet recruiting
Hunan Cancer Hospital
Changsha, Hunan, China · Not yet recruiting
Jiangxi Cancer Hospital
Nanchang, Jiangxi, China · Not yet recruiting
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China · Not yet recruiting
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China · Not yet recruiting
Sichuan Cancer Hospital
Chengdu, Sichuan, China · Not yet recruiting
Yunnan Cancer Hospital
Kunming, Yunnan, China · Not yet recruiting
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.